A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment

Šagud, Marina and Nikolac Perković, Matea and Vuksan-Ćusa, Bjanka and Maravić, Anja and Švob Štrac, Dubravka and Mihaljević Peleš, Alma and Živković, Maja and Kušević, Zorana and Pivac, Nela (2016) A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology, 233 (17). pp. 3259-3267. ISSN 0033-3158

[img] PDF - Accepted Version
Download (609kB)

Abstract

BACKGROUND: Various antidepressants occupy brain serotonin transporter (SERT), decrease platelet serotonin (5-HT) concentration, and normalize reduced plasma brain-derived neurotrophic factor (BDNF) concentrations in depressed patients. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. In addition to SERT inhibition, vortioxetine acts via different 5-HT receptors. To further elucidate its mechanism of action, we have investigated the effects of vortioxetine on platelet 5-HT and plasma BDNF concentrations in patients with major depression. ----- METHODS: Platelet 5-HT and plasma BDNF concentrations were determined in 44 healthy subjects at baseline and in 44 depressed patients before and after 4 weeks of treatment with vortioxetine (5-15 mg daily). Platelet 5-HT concentration was determined using the ortho-phthalaldehyde-enhanced fluorometric method, and plasma BDNF concentration using a commercial enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems). ----- RESULTS: At baseline, platelet 5-HT concentrations did not differ between depressed and control subjects, but plasma BDNF values were lower (p = 0.011; ω = 0.80) in depressed patients than in healthy subjects. Vortioxetine treatment significantly (p < 0.0001; ω = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004; ω = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values. Age, gender, and smoking were not significantly associated with platelet 5-HT and plasma BDNF concentrations. ----- CONCLUSION: Despite a novel mechanism of action, vortioxetine shares some common effects with other antidepressants. This study is the first to show that, in addition to clinical improvement, 4 weeks of treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF concentrations in depressed patients.

Item Type: Article
MeSH: Adult ; Aged ; Antidepressive Agents/therapeutic use ; Blood Platelets/metabolism ; Brain-Derived Neurotrophic Factor/blood ; Case-Control Studies ; Croatia ; Depressive Disorder, Major/blood ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Major/metabolism ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Piperazines/therapeutic use ; Prospective Studies ; Serotonin/metabolism ; Serotonin Uptake Inhibitors/therapeutic use ; Sulfides/therapeutic use
Departments: Katedra za psihijatriju i psihološku medicinu
Depositing User: Martina Žužak
Status: Published
Creators:
CreatorsEmail
Šagud, MarinaUNSPECIFIED
Nikolac Perković, MateaUNSPECIFIED
Vuksan-Ćusa, BjankaUNSPECIFIED
Maravić, AnjaUNSPECIFIED
Švob Štrac, DubravkaUNSPECIFIED
Mihaljević Peleš, AlmaUNSPECIFIED
Živković, MajaUNSPECIFIED
Kušević, ZoranaUNSPECIFIED
Pivac, NelaUNSPECIFIED
Date: September 2016
Date Deposited: 12 Jan 2018 08:46
Last Modified: 17 Aug 2020 07:12
Subjects: UNSPECIFIED
Related URLs:
URI: http://medlib.mef.hr/id/eprint/2774

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year